Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798398 | 1.00 | ADORA3 (0.49) | ADORA3HPGDADORA2AHINT1NT5E | |
| Phosphoric Acid SCHEMBL21489424 | 0.96 | NT5E (0.49) | ADORA3HPGDADORA2AHINT1NT5E | |
| Phosphoric Acid SCHEMBL21489243 | 0.96 | NT5E (0.49) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL4844756 | 0.88 | ADORA3 (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL546453 | 0.88 | ADORA3 (0.51) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL6537055 | 0.88 | ADORA3 (0.53) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL19352193 | 0.87 | ADORA3 (0.50) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL14594720 | 0.87 | ADORA3 (0.50) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL313652 | 0.87 | PDE4D (0.53) | ADORA3HPGDADORA2AHINT1NT5E | |
| SCHEMBL5203956 | 0.87 | PDE4D (0.53) | ADORA3HPGDADORA2AHINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| WO-2015164674-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015085318-A2 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015058069-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015051214-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015048744-A2 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA3 170/4885HPGD 1439/4885ADORA2A 174/4885 |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | ADORA3 4405/4885HPGD 4430/4885ADORA2A 4871/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | ADORA3 2303/4885HPGD 1710/4885ADORA2A 3850/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | ADORA3 1099/4885HPGD 3583/4885ADORA2A 2099/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ADORA3 415/4885HPGD 4496/4885ADORA2A 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.